WellStar Health System to Highlight New BVA-Driven Strategy That Significantly Reduces Kidney Injury Following LVAD Implantation Oak Ridge, TN, April 17, 2025 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom CV Transforum Spring’25 Conference being held at the Renaissance Orlando at SeaWorld in Orlando, FL from April 24-26, 2025. The Cardiovascular Transforum conference unites cardiovascular thought leaders from across the country to transform cardiovascular care together with leading industry innovators. Wellstar Health System’s Dr. Brian Howard will present findings showing how their Advanced Heart Failure program successfully reduced acute kidney injury rates following left ventricular assist device implantation through a multi-tiered approach centered on blood volume analysis (BVA). The presentation will share results from their retrospective cohort study and provide implementation strategies for attendees to replicate in their own programs. “We’re honored to have expert clinicians share their firsthand experience with BVA—why it matters, how to effectively integrate it into heart failure programs, and the meaningful impact it has on patient outcomes and quality of life,” said Michael Feldschuh, CEO and President of Daxor. BVA guided care has been shown in peer-reviewed studies to significantly improve multiple measures of patient outcomes including a reduction in 30-day mortality by 82%, 1-year mortality by 86%, 30-day readmissions by 56%, and results in a 55% reduction in length of stay when done on admission (P